Lambert-Eaton Myasthenic Syndrome Recurrence Induced by Pembrolizumab in a Patient with Non-small-cell Lung Cancer

A 73-year-old woman in complete remission from localized small-cell lung cancer associated with Lambert-Eaton myasthenic syndrome (LEMS) 22 years earlier was referred to our hospital and diagnosed with non-small-cell lung cancer. After three courses of pembrolizumab, an immune checkpoint inhibitor,...

Descripción completa

Detalles Bibliográficos
Autores principales: Takigawa, Yuki, Watanabe, Hiromi, Omote, Yoshio, Kurihara, Sunao, Inoue, Tomoyoshi, Fujiwara, Miho, Mitsumune, Sho, Onishi, Kiriko, Kudo, Kenichiro, Sato, Akiko, Sato, Ken, Fujiwara, Keiichi, Shibayama, Takuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10125817/
https://www.ncbi.nlm.nih.gov/pubmed/36047125
http://dx.doi.org/10.2169/internalmedicine.0072-22
Descripción
Sumario:A 73-year-old woman in complete remission from localized small-cell lung cancer associated with Lambert-Eaton myasthenic syndrome (LEMS) 22 years earlier was referred to our hospital and diagnosed with non-small-cell lung cancer. After three courses of pembrolizumab, an immune checkpoint inhibitor, the patient complained of muscle weakness, fatigue, ptosis, and dysarthria. The anti-voltage-gated calcium channel antibody level was elevated, and waxing was observed on a high-frequency repetitive stimulation test using an electromyogram. We diagnosed her with recurrence of LEMS as an immune-related adverse event (irAE) induced by pembrolizumab. After intravenous immunoglobulin therapy, the patient's symptoms improved, and she was discharged.

Ejemplares similares